Top Markets
#1 GEKKO GEKKO +52.86%
#2 TENDIES TENDIES +48.87%
#3 Helium Helium +46.85%
#4 Pons Pons +41.91%
#5 ADO Protocol ADO Protocol +39.18%
#6 Prom Prom +33.01%
#7 Collector Crypt Collector Crypt +20.14%
#8 Nillion Nillion +19.44%
#9 龙虾 (Lobster) 龙虾 (Lobster) +18.52%
#10 o1.exchange o1.exchange +18.40%
Coin of the day
GEKKO GEKKO
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
CARsgen Therapeutics Holdings Limited CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited

2171
Rang in Aktien #9600
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in... CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
Aktienkurs
$1.72
Zuletzt synchronisiert: 2026-08-28
Marktkapitalisierung
$981.92M
Veränderung (1 Tag)
-1.68%
Veränderung (1 Jahr)
-41.83%
Land
CN
Handel CARsgen Therapeutics Holdings Limited (2171)

Kategorie

Healthcare
Dividendenhistorie für CARsgen Therapeutics Holdings Limited (2171)
CARsgen Therapeutics Holdings Limited (Aktienkürzel: 2171) zahlte insgesamt 0 Dividenden.
Die Summe aller Dividenden (angepasst an Aktiensplits) beträgt: 0.00
Dividendenrendite (TTM): 0
Dividendenzahlungen für CARsgen Therapeutics Holdings Limited (2171) von 2026 bis 2026
Jährliche Dividendenzahlungen
Jahr Dividende (angepasst an Aktiensplits) ändert
Nicht genügend Daten für die angegebenen Daten.
Liste aller Dividendenzahlungen
Jahr Dividende ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenzahlungen ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Dividendenzahlungen Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH